Organization Profile

You just read:

Lilly Announces Positive Results for Emgality™ (galcanezumab) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments

News provided by

Eli Lilly Canada

Aug 08, 2019, 09:00 ET